PBAC's latest decision on Prasugrel: Recommended with restriction (2024). Considered for Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), in combination with aspirin.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2009
Submissions
3
2009 → 2024
Eligible population
Adults aged ≥18 years with acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), treated in combination with aspirin, excluding those with a known history of stroke or transient ischaemic attack.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Key trials
ISAR-REACT 5
Comparator
ticagrelor and clopidogrel
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis (CMA) only; no ICER calculated as prasugrel was assessed as non-inferior to comparators on efficacy and safety grounds.
ICER (historical)
$15k/QALY in an earlier submission (2009) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.